Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein
The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome that is characterized by the development of multiple vascular tumors and is caused by inactivation of the von Hippel-Lindau protein (pVHL). Here we show that pVHL, through its beta-domain, binds directly to hypoxia-inducible factor (HIF), thereby targeting HIF for ubiquitination in an alpha-domain-dependent manner. This is the first function to be ascribed to the pVHL beta-domain. Furthermore, we provide the first direct evidence that pVHL has a function analogous to that of an F-box protein, namely, to recruit substrates to a ubiquitination machine. These results strengthen the link between overaccumulation of HIF and development of VHL disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the presence of oxygen (typically > 5% O2), the HIF-α subunit is hydroxylated by PHDs in an iron and oxygen dependent manner, which leads to HIF-α polyubiquitination by pVHL, targeting HIF-α for proteasomal degradation (Figure 2) [8].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [8]
In the citing paper
“As described in the AdPROM section, VHL acts as the substrate receptor for the Cul2-Rbx1 E3 ligase complex, recruiting HIF1α for its ubiquitination and degradation [88].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [88]
Citations
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Huang, L. E., Gu, J., Schau, M., & Bunn, H. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.7987 · Cited by 2,113
Mitochondrial reactive oxygen species trigger hypoxia-induced transcription
Chandel, N. S., Maltepe, E., Goldwasser, E., Mathieu, C. E., Simon, M. C., & Schumacker, P. T. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11715 · Cited by 1,926 · cited 1×
“Whether hypoxia and desferroxamine utilize the same molecular mechanism(s) to stabilize HIF in vivo remains to be determine”
BackgroundSalceda, S., & Caro, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22642 · Cited by 1,674
Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
Stebbins, C. E., Kaelin, W. G., & Pavletich, N. P. (1999) · Science · doi:10.1126/science.284.5413.455 · Cited by 860
Self-citationStabilization of wild-type p53 by hypoxia-inducible factor 1α
An, W. G., Kanekal, M., Simon, M. C., Maltepe, E., Blagosklonny, M. V., & Neckers, L. M. (1998) · Nature · doi:10.1038/32925 · Cited by 827
Regulation of the Hypoxia-inducible Transcription Factor 1α by the Ubiquitin-Proteasome Pathway
Kallio, P. J., Wilson, W. J., O'Brien, S., Makino, Y., & Poellinger, L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6519 · Cited by 754
Tumour suppression by the human von Hippel-Lindau gene product
Iliopoulos, O., Kibel, A., Gray, S., & Kaelin, W. G. (1995) · Nature Medicine · doi:10.1038/nm0895-822 · Cited by 703
Self-citationBinding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C
Kibel, A., Iliopoulos, O., DeCaprio, J. A., & Kaelin, W. G. (1995) · Science · doi:10.1126/science.7660130 · Cited by 671 · cited 1×
“pVHL normally exists in cells as a complex with elongin B and elongin C rather than as a monome”
BackgroundSelf-citationKamura, T., Sato, S., Haque, D., Liu, L., Kaelin, W. G., Conaway, R. C., & Conaway, J. W. (1998) · Genes & Development · doi:10.1101/gad.12.24.3872 · Cited by 595 · cited 1×
“pVHL normally exists in cells as a complex with elongin B and elongin C rather than as a monome”
BackgroundSelf-citation
Cited by
Items 601–700 of 1,005
Hypoxic regulation of the noncoding genome and NEAT1
Choudhry, H., & Mole, D. R. (2015) · Briefings in Functional Genomics · doi:10.1093/bfgp/elv050 · Cited by 61
Ashida, S., Nishimori, I., Tanimura, M., Onishi, S., & Shuin, T. (2002) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-002-0374-x · Cited by 59
“…it has been reported that VHL forms part of a ubiquitin-ligase complex that targets HIF-a subunits for oxygen-dependent proteolysis (Maxwell et al. 1999; Ohh et al. 2000; Tanimoto et al. 2000; Cockman et al. 2000; Kamura et al. 2000) and CA9 is tightly regulated by HIF (Wykoff et al. 2000).”
Molecular Biology of Renal Cell Cancer and the Identification of Therapeutic Targets
Iliopoulos, O. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8948 · Cited by 67
The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis
Schoenfeld, A. R., Parris, T., Eisenberger, A. B., Davidowitz, E. J., Leon, M. D., Talasazan, F., Devarajan, P., & Burk, R. D. (2000) · Oncogene · doi:10.1038/sj.onc.1203985 · Cited by 62
“…of hypoxia-inducible genes such as vascular endothelial growth factor (VEGF), glucose transporter, GLUT1 and platelet derived growth factor (PDGF) B chain (Iliopoulos et al., 1996), likely via degradation of hypoxia-inducible factor (HIF) a subunits (Maxwell et al., 1999; Ohh et al., 2000).”
BackgroundBasic Research in Kidney Cancer
Oosterwijk, E., Rathmell, W. K., Junker, K., Brannon, A. R., Pouliot, F., Finley, D. S., Mulders, P., Kırkalı, Z., Uemura, H., & Belldegrun, A. S. (2011) · European Urology · doi:10.1016/j.eururo.2011.06.048 · Cited by 66
“[21] OhhM, Park CW, IvanM, et al.”
BackgroundSignaling pathways and targeted therapy for pulmonary hypertension
Adu‐Amankwaah, J., Shi, Y., Song, H., Ma, Y., Liu, J., Wang, H., Yuan, J., Sun, K., Hu, Q., & Tan, R. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02287-8 · Cited by 63
Nervous system involvement in von Hippel–Lindau disease: pathology and mechanisms
Vortmeyer, A. O., Falke, E., Gläsker, S., Li, J., & Oldfield, E. H. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1091-z · Cited by 62
“Mutations within the beta domain of VHL disrupt its interaction with HIF-alpha subunits leading to constitutive HIF-alpha stabilization and HIF activity [32, 135].”
BackgroundMutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma.
Morris, M. R., Hughes, D. J., Tian, Y.-M., Ricketts, C. J., Lau, K. W., Gentle, D., Shuib, S., Serrano‐Fernández, P., Lubiński, J., Wiesener, M. S., et al. (2009) · PubMed · Cited by 69
Du, Y., Zhang, J., Gong, L.-P., Feng, Z.-Y., Wang, D., Pan, Y., Sun, L., Wen, J., Chen, G., Liang, J., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.11.031 · Cited by 61
Li, X., Liu, X., Xu, Y., Liu, J., Xie, M., Wang, N., & Chen, S. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2544 · Cited by 57
Gao, Y., Wu, Z., Xie, L., Li, C., Mao, Y., Duan, Y., Han, B., Han, S.-F., Yu, Y., Lu, H., et al. (2017) · Nature Communications · doi:10.1038/ncomms15337 · Cited by 61
Jang, S., Redon, C. E., & Aladjem, M. I. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00019 · Cited by 60
MicroRNAs in the cornea: Role and implications for treatment of corneal neovascularization
Mukwaya, A., Jensen, L. D., Peebo, B. B., & Lagali, N. (2019) · The Ocular Surface · doi:10.1016/j.jtos.2019.04.002 · Cited by 57
“Under normal conditions, hypoxia-inducible factor 1 alpha (HIF1-α ) is degraded 57 , however, under hypoxia, HIF1-α is stabilised by the inactivation of prolyl hydroxylases (PHD) and factor inhibiting HIF-1 (FIH-1) 58,59 .”
Liu, X., Zhang, X., Peng, Z., Li, C., Wang, Z., Wang, C., Deng, Z., Wu, B., Cui, Y., Wang, Z., et al. (2020) · Advanced Science · doi:10.1002/advs.201902040 · Cited by 60
Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer
Singhal, S. S., Sehrawat, A., Sahu, M., Singhal, P., Vatsyayan, R., Rao Lelsani, P. C., Yadav, S., & Awasthi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.24767 · Cited by 57
Zheng, X., Ruas, J. L., Cao, R., Salomons, F. A., Cao, Y., Poellinger, L., & Pereira, T. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02236-05 · Cited by 56
“This process starts with the hydroxylation of the protein by specific prolyl hydroxylases (5, 15), followed by the recognition of HIF-1 by the VHL E3 ligase complex (10, 31, 41, 54) and subsequent ubiquitylation and proteasome-dependent degradation.”
BackgroundIdentification of novel VHL target genes and relationship to hypoxic response pathways
Maina, E. N., Morris, M. R., Zatyka, M., Raval, R. R., Banks, R. E., Richards, F. M., Johnson, C. M., & Maher, E. R. (2005) · Oncogene · doi:10.1038/sj.onc.1208649 · Cited by 57
Role of Exon 2-encoded β-Domain of the von Hippel-Lindau Tumor Suppressor Protein
Bonicalzi, M.-E., Groulx, I., de Paulsen, N., & Lee, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008295200 · Cited by 55
Glutamine Metabolism: Molecular Regulation, Biological Functions, and Diseases
Kumar, M. A., Baba, S. K., Khan, I. R., Khan, M. S., Husain, F. M., Ahmad, S., Haris, M., Singh, M., Akil, A. A., Macha, M. A., et al. (2025) · MedComm · doi:10.1002/mco2.70120 · Cited by 62
Targeting the Hepatocyte Growth Factor/c-Met Signaling Pathway in Renal Cell Carcinoma
Harshman, L. C., & Choueiri, T. K. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e31829e3c9a · Cited by 60
Gaumann, A. K. A., Schlitt, H. J., & Geissler, E. K. (2008) · Transplant International · doi:10.1111/j.1432-2277.2007.00610.x · Cited by 59
Regulation of obesity and insulin resistance by hypoxia-inducible factors
Kim, J., Ban, J.-J., Ruthenborg, R., & Cho, K. (2014) · Hypoxia · doi:10.2147/hp.s68771 · Cited by 53
PanIN-Specific Regulation of Wnt Signaling by HIF2α during Early Pancreatic Tumorigenesis
Criscimanna, A., Duan, L.-J., Rhodes, J. A., Fendrich, V., Wickline, E., Hartman, D. J., Monga, S. P. S., Lotze, M. T., Gittes, G. K., Fong, G.-H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0566 · Cited by 56
Pereira, T., Zheng, X., Ruas, J. L., Tanimoto, K., & Poellinger, L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209297200 · Cited by 59
von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility.
Kamada, M., Suzuki, K., Kato, Y., Okuda, H., & Shuin, T. (2001) · PubMed · Cited by 56
Dioxygenases as O2-dependent regulators of the hypoxic response pathway
Dann, C. E., & Bruick, R. K. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.140 · Cited by 62
A Role for Saccharomyces cerevisiae Cul8 Ubiquitin Ligase in Proper Anaphase Progression
Michel, J. J., McCarville, J. F., & Xiong, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210358200 · Cited by 56
Höpfl, G., Wenger, R. H., Ziegler, U., Stallmach, T., Gardelle, O., Achermann, R. E., Wergin, M., Kaser‐Hotz, B., Saunders, H., Williams, K. J., et al. (2002) · PubMed · doi:10.5167/uzh-12 · Cited by 56
Ladroue, C., Hoogewijs, D., Gad, S., Carcenac, R., Storti, F., Barrois, M., Gimenez-Roqueplo, A.-P., Leporrier, M., Casadevall, N., Hermine, O., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.044644 · Cited by 55
Belting, M., & Christianson, H. C. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12393 · Cited by 55
Watson, E., Yilmaz, L. S., & Walhout, A. J. M. (2015) · Annual Review of Genetics · doi:10.1146/annurev-genet-112414-055257 · Cited by 55
Ratcliffe, P. P., & Bishop, T. (2014) · Hypoxia · doi:10.2147/hp.s47598 · Cited by 62
Yang, S., Wang, B., Humphries, F., Hogan, A. E., O'Shea, D. B., & Moynagh, P. N. (2014) · Immunity · doi:10.1016/j.immuni.2014.11.013 · Cited by 61
“Under normoxic conditions, newly synthesized HIF-1a is labile by virtue of being subject to proline hydroxylation by three prolyl hydoxylases (PHDs), resulting in interaction with von-Hippel-Lindau (VHL) protein that recruits an elongin B-elongin C-cullin-2-ring box-1containing E3 ubiquitin ligase complex that targets…”
BackgroundHypoxia regulates glutamate receptor trafficking through an HIF‐independent mechanism
Park, E. C., Ghose, P., Shao, Z., Ye, Q., Kang, L., Xu, X. Z. S., Powell‐Coffman, J. A., & Rongo, C. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.499 · Cited by 58
“This modification enables VHL-1 to bind and ubiquitinate HIF-1, resulting in its proteolysis (Maxwell et al , 1999; Ohh et al , 2000; Ivan et al , 2001; Jaakkola et al , 2001; Min et al , 2002; Bishop et al , 2004; Shen et al , 2006).”
Von Hippel-Lindau Disease: A Genetic and Clinical Review
Haddad, N. M. N., Cavallerano, J. D., & Silva, P. S. (2013) · Seminars in Ophthalmology · doi:10.3109/08820538.2013.825281 · Cited by 56
“Substrates of this complex are the a subunits of the heterodimeric transcription factor hypoxia-inducible factor (HIF), leading to its ubiquitylation and proteasome-mediated degradation.(14)”
BackgroundJiang, Y., Vasconcelles, M. J., Wretzel, S., Light, A., Gilooly, L., McDaid, K., Oh, C.-S., Martin, C. E., & Goldberg, M. A. (2002) · Eukaryotic Cell · doi:10.1128/ec.1.3.481-490.2002 · Cited by 52
The Hypoxic Inducible Stress Response as a Target for Cancer Drug Discovery
Welsh, S. J., Koh, M. Y., & Powis, G. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.011 · Cited by 57
Ubiquitin/SUMO Modification Regulates VHL Protein Stability and Nucleocytoplasmic Localization
Cai, Q., & Robertson, E. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012636 · Cited by 65
“However, the main function of VHL is viewed as an adapter for targeting hypoxia-inducible factor (HIF) a subunit for proteolytic degradation [18,19].”
BackgroundRetractedLoss of VHL and Hypoxia Provokes PAX2 Up-Regulation in Clear Cell Renal Cell Carcinoma
Luu, V.-D., Boysen, G., Struckmann, K., Casagrande, S., von Teichman, A., Wild, P. J., Sulser, T., Schraml, P., & Moch, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2779 · Cited by 54
“The best-described function of pVHL as transcriptional regulator is its ability of targeting the α subunits of HIF for ubiquitin-mediated proteolysis via E3 ubiquitin protein ligase complex (3, 4).”
BackgroundFandrey, J., Schödel, J., Eckardt, K., Katschinski, D. M., & Wenger, R. H. (2019) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-019-02334-8 · Cited by 60
From Erythropoietin to Oxygen: Hypoxia-Inducible Factor Hydroxylases and the Hypoxia Signal Pathway
Ratcliffe, P. J. (2002) · Blood Purification · doi:10.1159/000065201 · Cited by 62
Oxygen: Modulator of Physiological and Pathophysiological Processes in the Liver
Kietzmann, T., Dimova, E., Flügel, D., & Scharf, J.-G. (2006) · Zeitschrift für Gastroenterologie · doi:10.1055/s-2005-858987 · Cited by 49
Hypoxia and Carbon Monoxide in the Vasculature
Kourembanas, S. (2002) · Antioxidants and Redox Signaling · doi:10.1089/152308602753666343 · Cited by 54
Hypoxia in bone metastasis and osteolysis
Todd, V. M., & Johnson, R. W. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.06.004 · Cited by 55
Copper-dependent and -independent hypoxia-inducible factor-1 regulation of gene expression
Zhang, Z., Qiu, L., Chen, L., Yang, H., Fu, H., Li, R., & Kang, Y. J. (2014) · Metallomics · doi:10.1039/c4mt00052h · Cited by 57
Zhou, L., & Yang, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023936 · Cited by 61
“This complex adds poly-ubiquitin chains onto the a subunits of the heterodimeric transcription factor hypoxiainducible factor (HIF), leading to proteasome-mediated degradation of HIF [4].”
BackgroundFunctional significance of erythropoietin in renal cell carcinoma
Morais, C., Johnson, D. W., Vesey, D. A., & Gobe, G. C. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-14 · Cited by 52
“The functional protein of VHL, pVHL, forms complexes with elongin B, elongin C, Rbx1 and cullin 2 to form a pVHL- E3 ubiquitin ligase complex (pVHL-E3 complex) [24-27].”
BackgroundFay, M. J., Longo, K. A., Karathanasis, G. A., Shope, D. M., Mandernach, C. J., Leong, J. R., Hicks, A., Pherson, K., & Husain, A. (2003) · Molecular Cancer · doi:10.1186/1476-4598-2-40 · Cited by 52
Yan, B. C., Mackinnon, A. C., & Al‐Ahmadie, H. A. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.7.1026 · Cited by 58
Kucejova, B., Sunny, N. E., Nguyen, A. D., Hallac, R., Fu, X., Peña-Llopis, S., Mason, R. P., DeBerardinis, R. J., Xie, X.-J., DeBose-Boyd, R., et al. (2011) · Oncogene · doi:10.1038/onc.2010.587 · Cited by 52
“The VHL protein (pVHL) functions as the substrate recognition subunit of an E3 ubiquitin ligase complex that targets, among others, hypoxia-inducible factor (HIF) a subunits for degradation (Maxwell et al., 1999; Cockman et al., 2000; Kamura et al., 2000; Ohh et al., 2000; Tanimoto et al., 2000).”
Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL
Hasanov, E., Chen, G., Chowdhury, P., Weldon, J., Ding, Z., Jonasch, E. W., Sen, S., Walker, C. L., & Dere, R. (2017) · Oncogene · doi:10.1038/onc.2016.495 · Cited by 52
Deregulation of E2-EPF Ubiquitin Carrier Protein in Papillary Renal Cell Carcinoma
Roos, F. C., Evans, A. J., Brenner, W., Wondergem, B., Klomp, J., Heir, P., Roche, O., Thomas, C., Schimmel, H., Furge, K. A., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.10.033 · Cited by 52
Self-citationKleymenova, E. (2003) · Carcinogenesis · doi:10.1093/carcin/bgh017 · Cited by 52
Womeldorff, M. R., Gillespie, D. L., & Jensen, R. L. (2014) · Neurosurgical FOCUS · doi:10.3171/2014.9.focus14496 · Cited by 52
mAKAP—A Master Scaffold for Cardiac Remodeling
Passariello, C. L., Li, J., Dodge‐Kafka, K. L., & Kapiloff, M. S. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000206 · Cited by 51
“HIF-1a is hydroxylated by a family of oxygen-sensitive dioxygenases called prolyl hydroxylases (PHD1, PHD2, and PHD3).(77) Hydroxylated HIF-1a is subsequently recognized by the von Hippel–Lindau protein (pVHL), which recruits the Elongin C ubiquitin ligase complex to ubiquitinate HIF-1a and to promote its proteasome-d…”
BackgroundHDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma
Ramakrishnan, S., Ku, S., Ciamporcero, E. S., Miles, K. M., Attwood, K. M., Chintala, S., Shen, L., Ellis, L., Sotomayor, P. C., Swetzig, W. M., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2604-7 · Cited by 52
“VHL protein is responsible for the proteasomal degradation of hypoxia inducible factors (HIF) by binding to the oxygen dependent domain on HIF, thus inhibiting downstream target genes involved in angiogenesis, glycolysis and cell cycle [2–4].”
BackgroundHypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
Casillas, A. L., Toth, R. K., Sainz, A. G., Singh, N., Desai, A. A., Kraft, A. S., & Warfel, N. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1318 · Cited by 49
“PIM kinase activity blocks the hydroxylation of HIF1/2a by PHDs HIF1/2a proteins are turned over through a well-defined pathway that involves hydroxylation by PHDs, binding to VHL, and subsequent degradation by the 26S proteasome (41).”
BackgroundProteasome‐mediated proteostasis: Novel medicinal and pharmacological strategies for diseases
Mishra, R., Upadhyay, A., Prajapati, V. K., & Mishra, A. (2018) · Medicinal Research Reviews · doi:10.1002/med.21502 · Cited by 51
Zhang, M.-X., Zhang, L., Fu, L., Yao, H., Tan, L., Feng, Z., Li, J., Lu, J. K., Pan, Y., Shu, G., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01971-7 · Cited by 52
Alleman, W. G., Tabios, R., Chandramouli, G. V. R., Aprelikova, O. N., Torres-Cabala, C. A., Mendoza, A., Rodgers, C., Sopko, N. A., Linehan, W. M., & Vasselli, J. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0516 · Cited by 55
“Under normoxic conditions, the VHL gene product forms a multimeric complex with elongin B, elongin C, Cul2, and Rbx1 (40–44), which in turn acts as a ubiquitin ligase targeting HIF for proteosomal degradation (45, 46).”
BackgroundPROTEIN INTERACTIONS AND DISEASE
Kann, M. G., Ofran, Y., Punta, M., & Radivojac, P. (2007) · Cited by 50
Design and Synthesis of Novel Small-Molecule Inhibitors of the Hypoxia Inducible Factor Pathway
Mooring, S. R., Jin, H., Devi, N. S., Jabbar, A. A., Kaluz, S., Liu, Y., Van Meir, E. G., & Wang, B. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201018g · Cited by 49
Koritzinsky, M., & Wouters, B. G. (2013) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2013.05.006 · Cited by 56
Gervais, M. L., Henry, P., Saravanan, A., Burry, T. N., Gallie, B. L., Jewett, M. A. S., Hill, R. P., Evans, A. J., & Ohh, M. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700684 · Cited by 51
Self-citationGenetic Basis of Cancer of the Kidney
Sudarshan, S., & Linehan, W. M. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.06.008 · Cited by 56
Barliya, T., Mandel, M., Livnat, T., Weinberger, D., & Lavie, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022849 · Cited by 50
“Stable transfection of VHL into C2 cells restored the E3 ubiquitin ligase complex functionality [19], including HIF-1a proteasomal degradation under normoxia and HIF-1a stabilization under hypoxic conditions (Fig.”
BackgroundKnockdown of hypoxia‐inducible factor‐1α by siRNA inhibits C2C12 myoblast differentiation
Ono, Y., Sensui, H., Sakamoto, Y., & Nagatomi, R. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20804 · Cited by 50
“Under normoxia, HIF-1a protein is known to be ubiquitinated by E3 ubiquitin ligase VHL in various cell types [Huang et al., 1998; Iwai et al., 1999; Lisztwan et al., 1999;Maxwell et al., 1999; Ohh et al., 2000].”
BackgroundPathogenetic mechanisms of polycythemia vera and congenital polycythemic disorders
Prchal, J. T. (2001) · Seminars in Hematology · doi:10.1016/s0037-1963(01)90135-0 · Cited by 59
Yoo, Y.-G., Christensen, J., & Huang, L. E. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2360 · Cited by 50
Lee, H., Lee, T., Lee, N., Yang, E. G., Lee, C., Lee, J., Moon, E., Ha, J., & Park, H. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr034 · Cited by 50
Choi, K.-O., Lee, T., Lee, N., Kim, J., Yang, E. G., Yoon, J. M., Kim, J. H., Lee, T. G., & Park, H. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.015271 · Cited by 53
“The tumor suppressor von HippelLindau (VHL) protein, which functions as an E3 ubiquitin ligase, interacts with the hydroxylated prolines of HIF-1 and brings about the assembly of a complex that activates a ubiquitin-dependent proteasome (Maxwell et al., 1999; Ohh et al., 2000; Min et al., 2002).”
BackgroundBiological Implications of Heme Metabolism
Sassa, S. (2006) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.38.138 · Cited by 53
JELKMANN, W. E. B. (2003) · Journal of Endocrinological Investigation · doi:10.1007/bf03345232 · Cited by 58
Gebregiworgis, T., Kano, Y., St-Germain, J., Radulovich, N., Udaskin, M. L., Mentes, A., Huang, R., Poon, B. P. K., He, W., Valencia-Sama, I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26526-y · Cited by 49
“RAS/RAF binding was assessed using the RAS activation assay kit from Millipore (17-218).”
MethodSelf-citationMacrophage Motility in Wound Healing Is Regulated by HIF-1α via S1P Signaling
Hutami, I. R., Izawa, T., Khurel‐Ochir, T., Sakamaki, T., Iwasa, A., & Tanaka, E. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168992 · Cited by 50
Datta, K., Mondal, S., Sinha, S., Li, J., Wang, E., Knebelmann, B., Karumanchi, S. A., & Mukhopadhyay, D. (2005) · Oncogene · doi:10.1038/sj.onc.1208912 · Cited by 56
Baba, M., Hirai, S.-I., Kawakami, S., Kishida, T., Sakai, N., Kaneko, S., Yao, M., Shuin, T., Kubota, Y., Hosaka, M., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204397 · Cited by 49
“One of the potential targets of the VHL-containing E3 enzyme is hypoxiainducible factor-1a (HIF-1a), a transcription factor responsible for the induction of the VEGF gene (Cockman et al., 2000; Maxwell et al., 1999; Ohh et al., 2000).”
BackgroundSiah: New Players in the Cellular Response to Hypoxia
Nakayama, K., & Ronai, Z. A. (2004) · Cell Cycle · doi:10.4161/cc.3.11.1207 · Cited by 61
Molecular pathology of von Hippel–Lindau disease and the VHL tumour suppressor gene
Richards, F. M. (2001) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399401002654 · Cited by 49
Yang, H., & Kaelin, W. G. (2001) · PubMed · Cited by 52
Self-citationThe Molecular Biology of Renal Cell Carcinoma
O’Keefe, S. J., Nathanson, K. L., & Rathmell, W. K. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.05.006 · Cited by 53
He, W., & Kang, Y. J. (2012) · Cardiovascular Toxicology · doi:10.1007/s12012-012-9174-y · Cited by 48
Identification of protein disulfide isomerase as an endothelial hypoxic stress protein
Graven, K. K., Molvar, C. A., Roncarati, J. S., Klahn, B. D., Lowrey, S. L., & Farber, H. W. (2002) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00359.2001 · Cited by 48
“Under normoxic conditions, HIF- is present at very low levels because of protein degradation by an E3 ubiquitin ligase containing the von Hippel-Lindau tumor suppressor protein (23, 32, 46).”
BackgroundHypoxia, Therapeutic Resistance, and Sphingosine 1-Phosphate
Cuvillier, O., Ader, I., Bouquerel, P., Brizuela, L., Gstalder, C., & Malavaud, B. A. (2013) · Advances in cancer research · doi:10.1016/b978-0-12-394274-6.00005-4 · Cited by 50
“…tumor suppressor gene product (pVHL) of theE3ubiquitin ligase complex (Iwai et al., 1999; Lisztwan, Imbert, Wirbelauer, Gstaiger, & Krek, 1999), leading to its polyubiquitination and proteasomal degradation (Cockman et al., 2000; Ohh et al., 2000; Tanimoto, Makino, Pereira, & Poellinger, 2000).”
Oxygen‐mediated endocytosis in cancer
Wang, Y., & Ohh, M. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01016.x · Cited by 51
Self-citationUbiquitination involved enzymes and cancer
Zhou, M., Chen, F., & Chen, H. (2014) · Medical Oncology · doi:10.1007/s12032-014-0093-6 · Cited by 50
Lee, J. H., Suk, J., Park, J., Kim, S. B., Kwak, S. S., Kim, J. W., Lee, C. H., Byun, B., Ahn, J. K., & Joe, C. O. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0191 · Cited by 53
“the rapid ubiquitination followed by proteosomal degradation (6, 7).”
BackgroundHasanov, E., & Jonasch, E. W. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1925248 · Cited by 50
Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery
Xi, J., Zhang, R., Chen, K., Yao, L., Li, M., Jiang, R., Li, X., & Fan, L. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105848 · Cited by 47
Activation of hypoxia-induced transcription in normoxia
Hägg, M., & Wennström, S. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.01.017 · Cited by 57
Prognostic Factors in Renal Cell Carcinoma
Shuch, B., LAM, J., Belldegrun, A. S., & Figlin, R. A. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.06.006 · Cited by 47
Familial adult renal neoplasia
Takahashi, M., Kahnoski, R. J., Gross, D., Nicol, D. L., & Teh, B. T. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.1.1 · Cited by 47
“4 The VHL gene was isolated from chromosome 3p25 5 and has characteristics of a tumour suppressor gene, that is, loss of function in both copies of the gene in CCRCC. 11 In the presence of mutated VHL protein, HIF-1a accumulates and increases its transcriptional activity resulting in overexpression of angiogenic pepti…”
BackgroundInfluentialKuo, C., Lin, C., & Hsu, T. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3196 · Cited by 46
“In VHL mutant ccRCC cells, HIF function is activated even in normal oxygen conditions (6,7), exhibiting heightened pseudohypoxic responses.”
BackgroundHIF-2α-pVHL complex reveals broad genotype-phenotype correlations in HIF-2α-driven disease
Tarade, D., Robinson, C. M., Lee, J. E., & Ohh, M. (2018) · Nature Communications · doi:10.1038/s41467-018-05554-1 · Cited by 48
Self-citationYakubu, R., Nieves, E., & Weiss, L. M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-15950-4_10 · Cited by 46
DNA Methylation Changes Are Associated With an Incremental Ascent to High Altitude
Childebayeva, A., Harman, T. S., Weinstein, J. B., Goodrich, J. M., Dolinoy, D. C., Day, T. A., Bigham, A. W., & Brutsaert, T. D. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01062 · Cited by 47
“In normoxic conditions, HIF-1α is hydroxylated by HIF prolyl hydroxylase (EGLN) and destined for degradation by ubiquitination via the von Hippel–Lindau ubiquitin ligase (Ohh et al., 2000; Epstein et al., 2001).”
BackgroundRole of the NEDD8 Modification of Cul2 in the Sequential Activation of ECV Complex
Sufan, R. I., & Ohh, M. (2006) · Neoplasia · doi:10.1593/neo.06520 · Cited by 45
Self-citationNatural compounds and the hypoxia-inducible factor (HIF) signalling pathway
Manolescu, B. N., Oprea, E., Buşu, C., & Cercasov, C. (2009) · Biochimie · doi:10.1016/j.biochi.2009.08.005 · Cited by 50
Transcriptional Regulation of Serine/Threonine Kinase-15 (STK15) Expression by Hypoxia and HIF-1
Klein, A. M., Flügel, D., & Kietzmann, T. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-01-0042 · Cited by 49
“…hydroxylation at P402 and P564 of human HIF-1 promotes binding of the von Hippel-Lindau (VHL) tumor suppressor protein (Maxwell et al., 1999; Ohh et al., 2000; Tanimoto et al., 2000; Hon et al., 2002; Min et al., 2002) and degradation via a proteasomal pathway (Salceda and Caro, 1997;…”
BackgroundAltinoz, M. A., Santaguida, C., Guiot, M., & Maestro, R. F. D. (2005) · Journal of Neurosurgery Spine · doi:10.3171/spi.2005.3.6.0495 · Cited by 46
Metadata
- Authors
- Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- Pennsylvania State University (US)
- Corresponding author
- Kaelin, William G.
- Venue
- Nature Cell Biology
- Published
- 2000-06-09
- Volume
- 2
- Issue
- 7
- Pages
- 423-427
- ISSN
- 1465-7392 (ISSN-L)
- 1476-4679
- OpenAlex
- W2147718842
- Cited by
- 1,577
- References
- 21
- Citations by year
- 2026: 23 · 2025: 36 · 2024: 46 · 2023: 36 · 2022: 49 · 2021: 56 · 2020: 59 · 2019: 45 · 2018: 40 · 2017: 50 · 2016: 52 · 2015: 45 · 2014: 62 · 2013: 66 · 2012: 70
- FWCI
- 33.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Keywords
- von Hippel-Lindau protein, hypoxia-inducible factor, ubiquitination, F-box protein, protein-protein interaction, alpha-domain, von Hippel-Lindau disease, tumor suppressor, vascular tumors, E3 ubiquitin ligase
- MeSH terms
- Elongin, Cell Extracts, Deferoxamine, DNA-Binding Proteins, HeLa Cells, Humans, Ligases, Mutation, Nuclear Proteins, Oxygen, Protein Binding, Protein Processing, Post-Translational, Proteins, Transcription Factors, Transfection, Tumor Cells, Cultured, Ubiquitins, Protein Structure, Tertiary, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Hypoxia-Inducible Factor 1, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.